Yu de fil lɛk se yu yay ɛn yu bɔdi nɔ de wok fayn? Lɛ wi tɔk bɔt Nyuromaylaytis Ɔptika (NMO)!

Sɔntɛnde, yu kin notis wantɛm wantɛm se yu de si chenj, ɔ yu kin fil lɛk se sɔm pat dɛn na yu bɔdi nɔ de wok fayn ɔ nɔ gɛt layf? Sɔntɛm yu yay kin at, ɔ i nɔ kin izi fɔ yu fɔ waka? Wan rizin kin de fɔ dɛn tin ya, ɛn tide wi go tɔk bɔt wan sik we nɔ kin bɔku smɔl, bɔt we rili impɔtant fɔ mek wi ɔl no bɔt. Dat na nyuromaylaytis optika, ɔ wi kɔl am `(NMO)` fɔ shɔt.

Wetin na Nyuromaylaytis Ɔptika?

Fɔ tɔk am simpul wan, Nyuromaylaytis Ɔptika (NMO) na wan sik we kin de fɔ lɔng tɛm ɛn we nɔ kin te. I kin mɔs afɛkt di we aw yu de si ɛn di ebul we yu ebul fɔ muv yu bɔdi. Imajin se wi bɔdi in yon difens sistɛm, we na di imyun sistɛm, kin mistek bigin fɔ atak sɔm pat dɛn na wi yon nervɔs sistɛm. Na dat wi kin kɔl ɔtoimyun disɔda. So, NMO na wan pan dɛn kayn sik ya.

Dɛn dɔn kɔl dis sik difrɛn nem dɛn as tɛm de go. Fɔs, dɛn bin de kɔl am Devic’s disease, afta wan Frɛnch nyurolɔjist Yujin Divik, we bin fɔs tɔk bɔt am. Bɔt insay 2015, wan intanashɔnal tim we gɛt masta sabi pipul dɛn bin gi am di nem Nyuromaylaytis Ɔptika Spɛktrum Disɔda (NMOSD). Bɔt bɔku dɔktɔ dɛn ɛn ɔda pipul dɛn stil de kɔl am NMO.

Trade, masta sabi pipul dɛn bin tink se NMO na wan rare variant of multiple sclerosis (MS). Bɔt naw i dɔn klia se na difrɛn, indipɛndɛnt kɔndishɔn frɔm MS .

Udat kin gɛt nyuromaylaytis ɔptika (NMO)?

Dis kכndyush כn kin bכku pan uman dεm. If yu tɔk roughly, 80% to 90% pan di sik pipul dɛm na uman dɛm. I kin afɛkt pipul dɛn we ol bitwin 30 ɛn 40. I nɔ kin izi fɔ mek yɔŋ pikin dɛn gɛt NMO, we min se na smɔl nɔmba nɔmɔ, lɛk 5% pan ɔl di sik pipul dɛn.

Pan ɔl we pipul dɛn we kɔmɔt na ɛni trayb ɔ trayb kin gɛt NMO, i nɔ kin afɛkt ɔlman di sem we. Pipul dɛn we kɔmɔt na Afrika, mɔ di wan dɛn we kɔmɔt na Afro-Karibian, kin gɛt mɔ risk. I kin afɛkt pipul dɛn bak we kɔmɔt na Eshia.

Aw kכmכn dεn kכl dis kכndyushכn `(NMO)`?

Infakt, NMO na sik we nɔ kin bɔku. I kin afɛkt bitwin 0.3 ɛn 4.4 pan ɛvri 100,000 pipul dɛm. Dat min se i kin bi bitwin 24,000 ɛn 350,600 pasɛnt dɛn ɔlsay na di wɔl.

Aw dis `(NMO)` de afɛkt mi bɔdi?

Fɔ ɔndastand aw NMO de afɛkt yu, i go fayn fɔ mek yu ɔndastand smɔl bɔt wi nervɔs sistɛm. Wi nervɔs sistɛm na di bren ɛn di spɛnal kɔd. Infakt, ivin di optik nɛv dɛn we de ɛp wi fɔ si na pat pan di bren.

we wi tek di bren εn di spεnal kכd tכgeda, wi kin kכl am di sεntri nεv sεstem. afta dat, di nεtwכk fכ di nεv dεm we de go כlsay na di bכdi dεn kכl am di pεrifεral nεv sεstem.

Wi nervɔs sistɛm kin kɛr infɔmeshɔn go ɛn kam na di bren. Dɛn kin du dis tru kemikal ɛn ilɛktrik signal dɛn. dis signal dεm de travul tru spεshal sεl dεm we dεn kכl nyuron dεm.

di pat we imכtant pas כl pan εvri nyuron na di aksכn. Dis tan lɛk wan an na di nyuron. Ilektrikal signal dεm de kכri along dis aksכn. na di εnd pan di aksכn de pat dεm we dεn kכl sinaps. Dis na di say we ilɛktrik signal dɛn kin bi kemikal signal. dis sinaps dεm na di say we di nyuron de kכnεkt εn kכmכnik wit כda nyuron dεm.

rawnd dis aksכn , wan tin we de protεkt we dεn kכl maylin de. Dis na fεt kεmikכl kכmpawnd dεm. di maylin sεt de εp di ilektrikal signal dεm fכ travul along di aksכn εn i de mek di aksכn nכ damej. (NMO) na wan sik we de mek yu nɔ gɛt di maylin we de pwɛl di maylin sheath. Dis tan lɛk aw di plastic sheath we de pan ilɛktrik waya kin pwɛl if yu pul am. we dεn pul di maylin sεt, di aksכn kin pwεl izi wan.

di damej we NMO kin mek kin afekt di nyuron dεm we de na tu spεsifi k say dεm:

1. Di optik nerve, we de kɔnɛkt yu yay to yu bren.

2. Yu spεnal kɔd. dis na di men sεntr usay dεn de kכlekt di nεv signal dεm bifo dεn rich na di bren.

NMO kin afekt mכltipכl lεvεl dεm na di spεnal kכd. dis kin afekt כl di nεv dεm we de kכnekt dכn di spεnal kכd we afekt.

Wetin na di sayn dɛm fɔ nyuromaylaytis optika (NMO)?

di NMO simptom dεm kin apin insay di fכm fכ "atak." Dis min se di sik kin kam wantɛm wantɛm, kin las fɔ shɔt tɛm, dɔn i kin go. Dɛn atak ya kin te frɔm sɔm dez to mɔnt. Bɔrku tɛm, dɛn atak ya kin tranga, ɛn sɔmtɛm kin pwɛl pɔrsin fɔ ɔltɛm. If na so i bi, di tin dɛn we kin apin kin de sote go ivin afta di atak dɔn.

Dɛn kin sheb di sayn dɛm fɔ NMO to tri men kategori dɛm:

• Optik nyuraytis: Dɛn simptom ya kin kam we di optik nɛv de swel (inflammation) na wan ɔ ɔl tu yu yay.
• Maylaytis: Dɛn simptom ya kin kam we di spaynal kɔd kin swel (inflammation).
• Di tin dɛn we kin ambɔg di we aw di bren de wok:dis dεm kin apin we NMO de afekt yu haypothalamus כ bren stεm, we na di men pat dεm na wi bכdi we de kכntro כtomatכk prכsεs dεm.

Optik nyuraytis

wi yay dεn de tek di layt we de kכmכt frכm di tin dεm we de rawnd wi εn de sεnd signal to di bren tru di optik nεv. Di bren de prosɛs dɛn signal dɛn de ɛn gi wi vishɔn.

Insay optik nyuraytis, di optik nεv de swel. Bikɔs nɔto bɔku ples de na da pat de na di ed, dis swɛlin kin put bɔku prɛshɔn pan di optik nɛv. Tink bɔt am, we wi swɛt wan an ɔ leg, i kin fil lɛk se i nɔ gɛt bɛtɛ trɛnk ɛn i kin at. na dat kin apin we prεshכn de pan di optik nεv.

Di sayn dɛm fɔ optik nyuraytis kin afɛkt wan ɔ ɔl tu di yay dɛm. Sɔntɛnde, wan yay kin afɛkt fɔs, dɔn di ɔda wan, ɔ ɔl tu di yay kin afɛkt di sem tɛm. Di sayn dɛm na:

• Ay pen: Dis pen kin bɔku, mɔ we yu de muv di yay.
• Blɔr vishɔn: Dis kin bɔku we yu taya.
• Yu nɔ de si sɔm pat ɔ kɔmplit wan: Yu kin lɔs ɔl ɔ pat pan yu yay na wan yay (fɔ ɛgzampul, yu kin lɔs di sɛntrɔm pan wetin yu de luk). Yu kin si bak we yu nɔ de si fayn ɔ yu nɔ de si di kɔlɔ igen.
• I nɔ izi fɔ si we layt nɔ de shayn: Dis kin mek i nɔ izi fɔ du tin lɛk fɔ drayv na nɛt.

Maylaytis we gɛt di sik

Maylaytis na inflamɛns na yu spɛshal kɔd. dis inflameshn kin put prεshכn pan di spεnal kכd εn di spεnal nεv dεm we de nia. dis kin mek di nεv signal dεm blכk pat כ kכmplit. we dεn blכk כl kayn nεv signal dεm, dεn kכl am transvas maylaytis.

di sayn dεm fכ maylaytis dipכnt pan usay di swel de εn us pat dεm na di spεnal kכd כ spεnal nεv dεm de afekt. If di swel put prεshכn pan di spεnal nεv dεm, di sayn dεm go apin na di pat dεm na di bכdi we de kכnekt dεn nεv dεm to di bren. if dεn kכmprεs di spεnal kכd, di simptom dεm go apin na כl di pat dεm na di bכdi we kכnekt to di spεnal nεv dεm we de dכn di pכynt we dεn kכmprεs.

Di sayn dɛm fɔ maylaytis na:

• di mכsul dεm wik כ paralayz: Dis kin afekt di pat dεm na di bכdi dεn we de dכn di εria we afekt na di spεnal kכd. Yu nɔ go ebul fɔ kɔntrol yu an ɛn fut, ɛn dis kin mek i nɔ izi fɔ waka ɔ tinap. if maylaytis apin na di sεvikal spεnal kכd, ivin di mכsul dεm we de brith kin paralayz, we kin kil.
• Spasticity: Dis kin apin we di mכsul dεm lכs di kכntrol signal dεm frכm di bren εn bigin fכ akt dεn wan. Dɔn di mɔsul dɛn kin stif ɛn dɛn kin twitch we pɔsin nɔ ebul fɔ kɔntrol.
• Pen:Maylaytis kin mek yu fil pen bikɔs ɔf prɛshɔn pan di spɛshal kɔd. Di pen kin bi bikɔs ɔf di swel insɛf, ɔ i kin bi bikɔs di nerv dɛm we afɛkt de sɛn pen signal di rɔŋ we.
• Inkontinɛns: Maylaytis kin ambɔg di nεv signal dεm we de kכntro di bכdi εn blad fכ wok, we kin mek yu nכ ebul fכ kכntinכn כ di bכdi in kכntinεns.
• Sεkswal disfכnkshכn: Maylaytis kin ambɔg di nεv signal dεm we de kכntrכl sεkswal fכnshכn כ כgan dεm.

Distɔblɛshɔn na di bren wok

Pan ɔl we i kɔmɔn fɔ si chenj na di bren pan di sik we dɛn kɔl multiple sclerosis (MS), i nɔ kin apin so ɔltɛm na NMO. Bɔt we dɛn kin apin, di we aw di bren de kɔntrol sɔm pan di tin dɛn we di bɔdi de du kin ambɔg. If dɛn disrɔpshɔn ya apin na di haypothalamus ɔ di bren stem, dɛn kin mek siriɔs prɔblɛm dɛn, ivin kil pɔsin.

Di bren stem na di pat we de dɔŋ pas ɔl na di bren. I de na di bak pat na di ed, na di bɔt. Dis pat rili impɔtant. Bikɔs i de kɔnɛkt di bren to di spɛnal kɔd, i de kɔntrol bak di ɔtomɛtik prɔses dɛn. כtomatik prכsεs na tin dεm we de apin we wi nכ de tink bכt dεm - tin dεm lεk fכ brith, bכdi prεshכn, swet.

If NMO afɛkt di bren stem, di sayn dɛm lɛk:

• Hiku dɛn we nɔ go ebul fɔ stɔp.
• I de it we yu nɔ go ebul fɔ stɔp (pruritus).
• Nɔs ɛn vɔmit fɔ no rizin.
• I nɔ de yɛri fayn igen.
• Fɔ si tu tin wan tɛm (diplopia), we yu nɔ ebul fɔ kɔntrol yu yay (nystagmus), ɔ ɔda prɔblɛm dɛn we yu gɛt we yu de kɔntrol yu yay.
• Fes palsi we pɔsin kin gɛt.
• Diziz ɔ filin fɔ spin (vertigo).
• Prɔblɛm wit bɔdi balans ɔ kɔdineshɔn (ataxia).
• Fes nerv pen (trigeminal nyuraljia).

di haypothalamus de jis oba di bren stem. I de kɔntrol bak di tin dɛn we di bɔdi de du ɔtomɛtik wan. If NMO afɛkt am, ɔda sistɛm dɛn na di bɔdi kin nɔ wok fayn bak. Fɔ ɛgzampul, NMO kin mek yu gɛt sayn dɛm fɔ narkolepsi (we pɔsin kin slip pasmak na de).

Wetin kin mek pɔsin gɛt nyuromaylaytis optika (NMO)?

Di masta sabi pipul dɛn stil nɔ ebul fɔ ɛksplen gud gud wan aw ɛn wetin mek NMO de divɛlɔp. Di tin dɛn we dɛn no naw ɔ we dɛn tink se kin mek i gɛt dis sik na:

• Di imyun sistɛm nɔ de wok fayn.
• Ɔda ɔtoimyun ɔ inflammatory kɔndishɔn dɛn.

Imyun sistɛm nɔ de wok fayn

NMO na wan sik we pɔsin kin gɛt we i de fɛt insɛf. Dis min se wi yon imyun sistɛm kin mistek atak wan pat pan wi yon bɔdi. insay dis kes, i de atak wi optik nεv dεm εn/כ spεnal kכd.

Naw tu ɔtoimyun fכm dεm de we dεn no fכ NMO:

• Akwaporin-4 (AQP4) antibodi dɛn:`(AQP4)` na wan protin we de fכm na di sεf fכ sכm sεl dεm na di nεv sεstem. Di wok we i de du na fɔ mek wata go insay ɛn kɔmɔt na di sɛl dɛn. di `(AQP4)` antibodi dεm de mistek tεl di imyun sistεm fכ atak dis protin. Dɔn di sɛl dɛn we gɛt dis prɔtin kin pwɛl. mכr dan 80% pan di pipul dεm we gεt `(NMO)` gεt dεn `(AQP4)` antibodi dεm ya na dεn bכdi.
• di maylin Oligodendrocyte Glycoprotein (MOG) antibodi dεm: MOG na protin we de εp fכ bil εn mεnten di maylin sεt we de rawnd nyuron dεm. di MOG antibodi dεm de mistek tεl di imyun sistεm fכ atak dis protin, we de afta dat de disrupt di maylin sεt we de rawnd nyuron dεm. Na lɛk 6.5% pan di pipul dɛm we gɛt NMO gɛt dis antibodi na dɛn blɔd.

Dis imyun sistɛm we nɔ de wok fayn kin apin bɔku tɛm fɔ rizin dɛn we wi nɔ no. Bɔt sɔm data sho se dis malfunction kin apin afta infɛkshɔn. Bitwin 15% ɛn 35% pan di pipul dɛm we gɛt NMO dɔn gɛt infɛkshɔn bifo dɛn gɛt di sayn dɛm fɔ NMO. Bɔt dɛn nid fɔ du mɔ risach fɔ no if dis na tru.

Naw di masta sabi pipul dɛm nɔ no wetin mek pipul dɛm we nɔ gɛt antibodi to ɛni wan pan di `(AQP4)` ɔ `(MOG)` (we na lɛk 13.5% pan pipul dɛm we gɛt di sik) kin gɛt `(NMO).` Dɛn kin klas dɛn kayn kes ya as `(idiopathic)`.

כlso, sכm masta sabi pipul dεm biliv se ``(MOG)`` antibodi-rεlatεd ``(NMO)`` na rili wan sεparat sik. Bɔt dɛn nid fɔ du mɔ risach bɔt dis, ɛn dɛn nɔ dɔn ɔfishal wan no yet se na difrɛn sik.

Ɔda ɔtoimyun ɔ inflammatory kɔndishɔn dɛn

Pan ɔl we NMO kin apin fɔ insɛf, i kin apin mɔ pan pipul dɛn we gɛt ɔda ɔtoimyun ɔ inflammatory kɔndishɔn. Bɔt dɛn nid fɔ du mɔ risach fɔ no if dɛn tin ya de mek ɔ ɛp fɔ mek NMO apin.

Dɛn kayn tin dɛn ya na:

• Lupus `(Lupus - sistεmik lupus εrytematosus)`
• Siliak sik we dɛn kin gɛt
• Di sik we dɛn kɔl Sjögren in sindrom
• Sarkoidosis we pɔsin kin gɛt
• Myasthenia gravis we gɛt di sik
• Antifosfolipid sindrom we gɛt di sik

Di tin dɛn we de mek pɔsin gɛt jɛnɛtiks

di masta sabi pipul dεm de sכspεkt se jεnεtik fכktכ dεm kin ple bak pan NMO. Wan rizin na bikɔs dis sik kin bɔku pan sɔm etnik grup dɛn. Wan ɔda wan na dat, lɛk 3% pan di NMO pasɛnt dɛn kin rɔn na di sem famili. Pan ɔl we no pruf nɔ de fɔ se NMO na sik we pɔsin kin gɛt frɔm in mama ɛn papa, sɔm tin dɛn kin de we kin mek i gɛt mɔ chans fɔ mek NMO.

Yu tink se nyuromaylaytis optika (NMO) kin pas frɔm pɔsin to ɔda pɔsin?

Naw, no pruf nɔ de fɔ se NMOSD ɔ NMO kin pas frɔm pɔsin to ɔda pɔsin.

Aw dɛn kin no se pɔsin gɛt nyuromaylaytis optika (NMO)?

di mכst imכtant difrεns bitwin mכltipl sklεrosis (MS) εn NMO na dat sכm tεst dεm kin kכnfכm if pכsin gεt NMO. Dɔktɔ kin yuz wan kɔmbaynshɔn fɔ dɛn tin ya fɔ no if i gɛt NMO:

• Blɔd tɛst: Wan pan di impɔtant tin dɛn we dɔktɔ dɛn gɛt fɔ no if yu gɛt NMO na fɔ chɛk yu blɔd fɔ si if i gɛt antibodies to AQP4 ɔ MOG. Pan ɔl we blɔd tɛst nɔ kin ebul fɔ kɔnfɔm NMO ɔltɛm (bikɔs lɛk 13.5% pan di kes dɛm nɔ gɛt ɛni antibodi we dɛn kin no), i rili yusful fɔ mek dɛn no di sik.
• Magnetic Resonance Imaging (MRI) Scan: MRI skan kin ɛp mɔ fɔ no if yu gɛt NMO. Dis kכndyushכn kin mek chenj dεm na yu spayna εn כda pat dεm na yu sεntri nεv sεstem we dεn kin no pan MRI skan. Wi kin no dɛn tin ya klia wan frɔm di chenj dɛn we dɛn kin si pan MS, so dɔktɔ dɛn kin kɔnfirm se nɔto MS.
• Fyzikal ɛn nyurolɔjik ɛgzam: Dɛn tɛst ya kin luk fɔ sayn ɛn simptom dɛm we kin bi bikɔs ɔf NMO. Di nyurolɔjik ɛgzam impɔtant mɔ bikɔs i kin no di prɔblɛm dɛn we de wit yu sɛns, riflɛks, mɔsul muvmɛnt, balans, ɛn aw yu fes de wok.
• Pɔsin in pasɔnal ɛn mɛdikal istri: Insay dis, di dɔktɔ go aks yu kwɛstyɔn bɔt yu wɛlbɔdi, di sayn dɛm, ɛn di ditel dɛm bɔt yu pasɔnal ɛn mɛdikal istri.

Dɛn kin du ɔda tɛst dɛn bak, bikɔs yu dɔktɔ kin fil se i impɔtant fɔ pul ɔda tin dɛn we kin apin to yu. Yu dɔktɔ kin tɛl yu mɔ bɔt di tɛst dɛn we i kin tɛl yu fɔ du ɛn wetin mek dɛn kin tɛl yu fɔ du dɛn.

Aw dɛn kin trit nyuromaylaytis optika (NMO)? Yu tink se wan mɛrɛsin de fɔ mɛn am?

NMO nɔ go ebul fɔ mɛn ɔltogɛda. Bɔt bikɔs dɛn de du risach, dɛn kin ebul fɔ trit di sik. Bikɔs NMO na ɔtoimyun sik, tu men tritmɛnt opshɔn dɛn de: akyu tritmɛnt ɛn lɔng tɛm mɛnejɛmɛnt.

• Akyu tritmɛnt: Dis kin pe atɛnshɔn fɔ trit di kwik ifɛkt dɛm we NMO atak kin gɛt, mɔ di swɛlin. Bɔku tɛm dɛn kin du dis wit kɔtikosterɔyd (ɔ ɔda kayn mɛrɛsin we de ridyus di swel lɛk aw dɔktɔ tɛl am). Akyu tritmɛnt rili impɔtant bikɔs i de ridyus di risk fɔ damej fɔ ɔltɛm frɔm atak.
• Fɔ lɔng tɛm manejmɛnt:NMO na bikɔs yu imyun sistɛm mistek atak yu nervɔs sistɛm. Fɔ manej am min fɔ stɔp ɔ chenj yu imyun sistɛm. Dis kin mek i nɔ ebul fɔ pwɛl yu nervɔs sistɛm. Dis kin ɛp fɔ mek NMO atak nɔ apin, ɔ at ɔl fɔ stɔp aw dɛn bad ɛn aw lɔng dɛn kin las. Di masta sabi pipul dɛn kin se dis tritmɛnt fɔ pipul dɛn we gɛt ɛn we nɔ gɛt AQP4 antibodi.

Us kayn mɛrɛsin ɔ tritmɛnt dɛn kin yuz?

Bɔku mɛrɛsin ɛn tritmɛnt dɛn de we kin ɛp fɔ trit NMO:

• Anti-inflammatory drugs: Dɛn drɔgs ya de ridyus inflammation na yu nervous system. di mεdikeshכn we dεn kin yus fכ dis na kכtikostεroyd lεk prεdnison. Dɔktɔ dɛn kin stat dɛn mɛrɛsin ya insay dɛn bɛlɛ (IV). Dɛn kin gi dɛn we yu de na ɔspitul. Afta yu dɔn kɔmɔt na ɔspitul, yu dɔktɔ kin chenj yu to di sem kayn mɛrɛsin we yu kin tek wit yu mɔt.
• Plasma exchange (plasmapheresis): If stɛroyd nɔ ɛp, yu dɔktɔ kin tɛl yu fɔ du wan tin we dɛn kɔl plasma exchange. Dis min se yu fɔ pul di plasma na yu blɔd ɛn put di plasma we pɔsin we mach yu blɔd gi. We yu pul sɔm pan yu plasma ɛn put di plasma we yu gi yu, dɛn kin pul sɔm pan di imyun sɛl dɛn ɛn di kemikal mak dɛn (we de mek di imyun rispɔns strɔng) na di plasma. Dis kin mek yu bɔdi nɔ ebul fɔ fɛt di sik ɛn i kin mek yu nɔ swel.
• Intravenous Immunoglobulin (IVIG): Dis we aw dɛn kin du am na fɔ injekt plasma insay yu bɔdi tru wan IV. Di plasma we yu de gɛt gɛt imyunoglobulin dɛn. Dat min se, plasma we gɛt antibodi dɛn frɔm di wan dɛn we gi am. Dɛn tin ya nɔ de atak yu nervɔs sistɛm lɛk aw yu yon imyun sistɛm de du.
• Immunosuppressants: Dis na mɛrɛsin dɛn we yu nid fɔ tek ɔltɛm. Dɛn kin gi sɔm pan dɛn na di bɛlɛ (IV), we dɛn kin du na klinik usay dɛn kin put infushɔn ɔ na di sem kayn mɛrɛsin. Ɔda wan dɛn kin kam as pils, we yu kin tek na os. Bɔrku pipul dɛn nid fɔ tek dɛn pils ya fɔ lɔng lɔng tɛm, sɔmtɛm dɛn kin tek dɛn wan ol layf.

Wetin na di sayd ɛfɛkt ɔ kɔmplikeshɔn dɛm wae de kam wit de tritmɛnt?

De sayd effekt wae de tritment de dipen pan bɔrku tin, lɛk de drɔg, aw yu sik bad, ɛn yu mɛdikal histri. Bɔt wan sayd ɛfɛkt we di mɛrɛsin dɛn we de mek yu nɔ ebul fɔ fɛt di sik kin rili klia: dɛn kin ridyus yu imyun rispɔns.

Yu imyun sistεm de protεkt yu frכm fכrin invayda dεm lεk vayrus, baktri, fכn, εn parasayt. I de mek bak di sɛl dɛn nɔ de biev fayn. If yu bɔdi in sɛl dɛn nɔ de biev fayn, di imyun sistɛm in wok na fɔ invayt ɛn pwɛl dɛn (kansa na we di sɛl dɛn nɔ de biev fayn, ayd frɔm di imyun sistɛm, ɛn bɔku we yu nɔ ebul fɔ kɔntrol).

Pan ɔl we if yu tek di mɛrɛsin dɛn we de mek yu bɔdi nɔ gɛt bɛtɛ wɛlbɔdi, dat kin ɛp fɔ mek NMO nɔ atak yu, dɛn kin mek bak yu bɔdi nɔ ebul fɔ fɛt sɔm infɛkshɔn dɛn. Dɛn kin mek yu gɛt sɔm kayn tɔŋ dɛm bak (kansa ɛn nɔr gɛt kansa). If yu de tek mɛrɛsin we de mek yu bɔdi nɔ gɛt bɛtɛ wɛlbɔdi, yu fɔ tek sɔm tin dɛn fɔ mek yu nɔ sik. Yu kin nid bak fɔ gɛt vaysin agens sik dɛn we pɔsin kin gɛt lɛk COVID-19, influenza (flu), ɛn nyumonia, we kin rili bad ɛn ivin kil we yu imyun sistɛm wik.

Aw kwik a go fil fayn afta dɛn dɔn trit mi? Aw lɔng i go tek fɔ mek yu wɛl afta yu dɔn gɛt tritmɛnt?

Di tritmɛnt ɛn rikavari schedule fɔ NMO kin difrɛn, bikɔs bɔku tin dɛn kin afɛkt dis. Yu dɔktɔ na di bɛst say fɔ no bɔt dis. I kin tɛl yu wetin na di tɛmlayn we go mɔs bi na yu eria, ɛn wetin yu kin du fɔ ɛp wit di prɔses.

Wetin a fɔ ɛkspɛkt if a gɛt nyuromaylaytis ɔptika (NMO)?

If yu gɛt NMO, yu kin ɛkspɛkt dis kɔndishɔn fɔ bigin witout bɔku wɔnin. Sɔm pipul dɛn kin gɛt infekshɔn na dɛn respiratory infection ɔr ɔda sik bifo i kam, bɔt dat kin apin na lɛk wan pat pan tri pat (ɔ ivin smɔl) pan di kes dɛm.

NMO atak kin mek yu gɛt prɔblɛm wit yu yay bikɔs i kin afɛkt yu optik nɛv dɛn. Dɛn kin mek yu yay fil pen ɛn yu nɔ kin si fayn. Dɛn kin wɔs fɔ sɔm dez ɔr wik ɛn den kin pasmak. If di optik nɛv dɛn dɔn pwɛl bad bad wan, dɛn sayn ya kin de fɔ ɔltɛm, bɔt tritmɛnt kin ɛp fɔ mek dɛn nɔ pwɛl fɔ ɔltɛm.

NMO de afekt di lכw pat pan yu bren - di bren stεm - εn yu spεnal kכd. I kin mek yu bɔdi in ɔtomɛtik prɔses nɔ de wok fayn, ɛn mek tin dɛn lɛk nɔs, vɔmit, ɛn hiku we yu nɔ ebul fɔ kɔntrol.

If maylaytis kam bad bad wan, di prɛshɔn we de na di spɛshal kɔd kin ambɔg di nerve signal dɛm to di say we di sik afɛkt ɔ ɔl di pat dɛm na di bɔdi we de dɔŋ am. Dis kin mek di mɔsul dɛn wik, paralayz, ɛn nɔ kin fil fayn dɔŋ di say we di sik afɛkt. Dis kin bi siriɔs if di mɔsul dɛm we de kɔntrol aw pɔsin de blo afɛkt, we kin mek i paralayz ɔ di mɔsul dɛn wik. If yu trit yu kwik kwik wan, dat kin mek dɛn tin ya nɔ go de sote go.

(NMO) na wan sik we pɔsin kin gɛt we i de fɛt insɛf. Dis min se i kin apin we yu imyun sistɛm mistek atak sɔm pat dɛn na yu yon bɔdi. If na so i bi, yu imyun sistɛm de tɔch yu nervɔs sistɛm. Di tritmɛnt fɔ dis sik kin involv fɔ stɔp yu imyun sistɛm fɔ lɔng tɛm. I sɔri fɔ no se dis kin mek yu gɛt mɔ sik as sayd ɛfɛkt. Pipul dɛm wae de tek mɛrɛsin wae de mek dɛn nɔr de fil fayn, nid fɔ tek tɛm fɔ mek dɛn nɔr gɛt sik.

Aw lɔŋ nyuromaylaytis optika (NMO) kin las?

NMO kin mek atak, min se di sayn dɛm kin apia wantɛm wantɛm. Fɔ pipul dɛm wae gɛt antibodi to ɛni wan pan AQP4 ɔ MOG, NMO na wan kɔndishɔn fɔ ɔl dɛn layf. Naw, pipul dɛm wae gɛt dis sik fɔ tek mɛrɛsin wae de mek dɛn nɔr de fil fayn fɔ lɔng tɛm, sɔmtɛm fɔ di res ɔf dɛn layf, fɔ mek dɛn nɔr gɛt atak.

Bitwin 10% ɛn 20% pan pipul dɛm wae gɛt NMO kin gɛt wan atak nɔmɔ ɛn nɔr kin ɛva gɛt ɔda wan. Dis kin apin mɔ pan pipul dɛm we nɔ gɛt antibodi to ɛni wan pan AQP4 ɔ MOG. Bɔt no we nɔ de fɔ no fɔ tru, so yu dɔktɔ go tɛl yu fɔ tek dɛn mɛrɛsin ya fɔ mek yu nɔ gɛt atak.

Wetin na di fiuja lukin-grɔn fɔ nyuromaylaytis ɔptika (NMO)?

Trade, NMO na bin sik we nɔ bin gɛt bɛtɛ prɔgnosis. Bɔt bikɔs ɔf di tin dɛn we dɛn dɔn fɛn bɔt di imyun ɔrijin fɔ di sik, masta sabi pipul dɛn no naw se NMO na wan sik we dɛn kin trit. di mεdikeshכn dεm we de mεnεj di kכndyushכn de rεdכks di rεt fכ rilaps bay bitwin 72% εn 88%. di fayv ia rεt we de liv wit dis kכndyushכn de bitwin 91% εn 98%.

Pipul wae gɛt NMO wae kin gɛt bɔrku atak kin lɔs sɔm abiliti dɛm, lɛk fɔ si ɛn muv. Na lɛk 22% pan pipul dɛn kin wɛl ɔlsay frɔm di ifɛkt dɛm we NMO kin gɛt ɛn dɛn kin gɛt ɔl dɛn abiliti bak. Na lɛk 7% nɔ kin wɛl atɔl. di rεst 71% de rεkכv at le pat, bכt dεn kin gεt ifekt dεm we de kכntinyu.

Aw a go ridyus di risk fɔ gɛt nyuromaylaytis optika (NMO)? Yu tink se dɛn go ebul fɔ stɔp am?

NMO kin apin we yu nɔ bin de ɛkspɛkt ɛn fɔ rizin dɛn we dɔktɔ dɛn stil nɔ ɔndastand gud gud wan. So, no we nɔ de fɔ mek i nɔ gɛt am ɔ fɔ ridyus di risk fɔ gɛt am.

Aw a kin kia fɔ misɛf?

NMO na wan kɔndishɔn we pɔsin kin ebul fɔ manej. Yu dɔktɔ go gayd yu fɔ no aw fɔ kia fɔ yusɛf. Sɔm pan di impɔtant tin dɛn we yu go du na:

• Tek yu mɛrɛsin kɔrɛkt wan: Ilɛksɛf yu de wɛl frɔm NMO atak ɔ yu dɔn go lɔng tɛm we yu nɔ gɛt atak, i impɔtant fɔ tek yu mɛrɛsin lɛk aw dɛn tɛl yu fɔ tek. Mɛrɛsin kin ɛp fɔ mek yu nɔ gɛt ɔ ridyus di damej we pɔsin kin gɛt we i de atak am naw ɛn i kin mek i nɔ gɛt atak tumara bambay. Nɔ stɔp fɔ tek dis mɛrɛsin we yu nɔ tɔk to yu dɔktɔ.
• Si yu dɔktɔ lɛk aw dɛn se:I rili impɔtant fɔ si yu dɔktɔ bak we yu gɛt NMO. Dis go mek yu dɔktɔ ebul fɔ wach aw di sik de ambɔg am. I kɔmɔn fɔ du blɔd tɛst ɔltɛm we yu gɛt NMO. Dis go mek yu dɔktɔ si aw yu imyun sistɛm de wok fayn fayn wan. Dɔn dɛn kin chenj yu mɛrɛsin(dɛn) if nid de.
• Tek tɛm fɔ mek yu gɛt wɛlbɔdi: If yu tek mɛrɛsin dɛn we de mek yu bɔdi nɔ gɛt bɛtɛ wɛlbɔdi, dɛn kin mek yu imyun sistɛm nɔ ebul fɔ atak yu nervɔs sistɛm. I sɔri fɔ no se dɛn kin ridyus yu imyun sistɛm bak fɔ fɛt di sik dɛn lɛk kol, flu, COVID-19, nyumonia, ɛn urinary tract infection (UTIs). Was yu an ɔltɛm (wit sop ɛn wata ɔ yu gɛt rɔm fɔ was yu an). Dipen pan di ɔl risk we yu gɛt, yu dɔktɔ kin se yu fɔ wɛr mask na pɔblik ɔ fɔ tek ɔda tin dɛn fɔ tek tɛm wit.

Ustɛm a fɔ kɔl mi dɔktɔ?

Pipul dɛm wae de tek mɛrɛsin wae de mek dɛn nɔr de fil fayn kin gɛt bɔrku risk fɔ sik frɔm ivin kɔmɔn infɛkshɔn dɛm, ivin di wan dɛm wae nɔr kin siriɔs. If pɔsin we de tek imyunosuppressant gɛt ɛni wan pan dɛn sayn ya, i fɔ kɔl in dɔktɔ:

• Taya pasmak (fɔ fil taya ɔ taya pasmak) ɔr wik.
• Nɔs ɛn vɔmit.
• Di wet we pɔsin kin chenj we i nɔ bin de ɛkspɛkt.
• Fɔ pis pas aw yu kin pis, yu bak kin pen, ɔ yu kin fil pen ɔ bɔn we yu de pis (dɛn tin ya na sayn dɛn we de sho se yu gɛt infekshɔn na yu urinary tract).
• Di sayn dɛm fɔ di ɔpa respiratory tract infection, lɛk fɔ kɔf, fɔ sniz, fɔ rɔn na yu nos, ɔ fɔ gɛt trot we de at.
• Ɔda sayn dɛn we de sho se yu gɛt di sik, lɛk fiva, kol, ɛn mɔsul dɛn we de at.

Wetin na di difrεns bitwin nyuromaylaytis optika `(NMO)` εn mכltipכl sklεrosis `(MS)`?

NMO ɛn multiple sclerosis (MS) na sik dɛm wae gɛt bɔrku tin wae fiba ɛn wae de ɔvalap simptom dɛm. Fɔ lɔng tɛm, masta sabi pipul dɛn bin mistek tink se NMO na wan kayn MS. Bɔt di wan dɛn we de stɔdi bɔt dis dɔn no naw se na difrɛn tin dɛn we kin apin.

di men difrεns bitwin `(NMO)` εn `(MS)` na dat labכtכri tεst kin εp fכ no di antibodi dεm we de mek `(NMO)` (pan כl we dεn nכ kin no di antibodi dεm כltεm). Di tritmɛnt fɔ `(NMO)` ɛn `(MS)` dɛnsɛf difrɛn, ɛn sɔm tritmɛnt fɔ `(MS)` kin mek di simptom dɛm fɔ `(NMO)` wɔs.

Fɔ tɔk am simpul wan, Nyuromaylaytis Ɔptika (NMO) na wan sik we nɔ kin bɔku ɛn we kin de fɔ lɔng tɛm. I kin apin we yu yone imyun sistεm atak spεshal pat dεm na yu sεntri nεv sεstem. Wan tɛm dɛn bin de tink se na wan kayn sik we nɔ kin apin so ɔltɛm we dɛn kɔl multiple sclerosis (MS), bɔt naw dɛn dɔn no se na difrɛn sik. Nɔ lɛk MS, bɔku pan di kes dɛm fɔ NMO kin kɔnfyus wit lab tɛst. Dis kin mek dɔktɔ dɛn ebul fɔ no ɛn trit am kwik kwik wan.

Di tin we impɔtant pas ɔl fɔ mɛmba (Take-Home Message) .

So, pan ɔl we i kin tan lɛk se na wɔd we de mek pɔsin fred, yu fɔ mɛmba se gud tritmɛnt dɛn de fɔ am naw . Nɔr lɛk aw i bin de trade, bɔrku mɔr infɔmeshɔn de bɔt dis sik naw, so i impɔtant fɔ go to dɔktɔ jɔs lɛk aw yu bigin fɔ gɛt di sik ɛn gɛt di rayt diagnosis.

• If yu gɛt chenj na yu yay wantɛm wantɛm, yu nɔ de fil fayn, ɔ yu wik, nɔ ignore am. Go to dɔktɔ wantɛm wantɛm.
• `(NMO)` nɔto `(MS)`. Di tritmɛnt fɔ dɛn tu pipul ya difrɛn. So, fɔ no di sik kɔrɛkt wan rili impɔtant.
• Di tritmɛnt dɛm we de naw kin kɔntrol di NMO atak dɛm ɛn ridyus di risk fɔ atak dɛm tumara bambay. I impɔtant fɔ tek di mɛrɛsin jɔs lɛk aw yu dɔktɔ tɛl yu fɔ tek am.
• We yu de tek mɛrɛsin we de stɔp di imyun sistɛm, tek tɛm spɛshal fɔ protɛkt yusɛf frɔm infɛkshɔn.

A op se dis infɔmeshɔn go ɛp yu. If yu gɛt ɛni ɔda kwɛstyɔn bɔt dis, nɔ shek fɔ aks yu dɔktɔ ɔ midwayf. Stay wit wɛlbɔdi!

` nyuromaylaytis optika, NMO, nεv sistεm, optik nεv, spεnal kכd, imyun sistεm, simptom dεm, maylin